The short version of obesity research fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-10. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
=== European action === PFOA contaminated waste was incorporated into soil improver and spread on agricultural land in Germany, leading to PFOA drinking water contamination of up to 0.519 parts per billion. The German Federal Environmental Agency issued guidelines for the sum of PFOA and PFOS concentrations in drinking water: 0.1 parts per billion for precaution and 0.3 parts per billion for a threshold. Residents were found to have a 6–8 factor increase of PFOA serum levels over unexposed Germans, with average PFOA concentrations in the 22–27 parts per billion range. An expert panel concluded that "concentrations were considered too low to cause overt adverse health effects in the exposed population". In the Netherlands, after questions by members of Parliament, the minister of Environment ordered a study into the potential exposure to PFOA of people living in the vicinity of the DuPont factory in Dordrecht. The report was published in March 2016 and concluded that "prior to 2002 residents were exposed to levels of PFOA at which health effects could not be ruled out". As a result of this, the government commissioned several further studies, including blood tests and measurements in drinking water. PFOA was identified as a PBT substance in the EU in 2013. It was then included in the candidate list of substances of very high concern. In 2017, PFOA, its salts and PFOA-related substances were added to annex XVII (restriction) of the REACH Regulation.
=== Examples of "limiting" amino acids in plant protein === According to WHO, human need for proteins is 0.66 g per kg of bodyweight per day. A 70 kg person has an estimated protein requirement of 46.2 g (70 kg x 0.66 g/kg). In addition, there is a specific need of essential amino acids quantities. See Essential amino acid#Recommended daily intake for a table of the values; the tables below use a percentage of the requirement.
== History == The first studies measuring drugs in biological fluids were carried out to determine possible overdosing as part of the new science of forensic medicine/toxicology. Initially, nonspecific assays were applied to measuring drugs in biological fluids. These were unable to discriminate between the drug and its metabolites; for example, aspirin (c. 1900) and sulfonamides (developed in the 1930s) were quantified by the use of colorimetric assays. Antibiotics were quantified by their ability to inhibit bacterial growth. The 1930s also saw the rise of pharmacokinetics, and as such the desire for more specific assays. Modern drugs are more potent, which has required more sensitive bioanalytical assays to accurately and reliably determine these drugs at lower concentrations. This has driven improvements in technology and analytical methods.
The league's official statement concluded: "Reid strongly supports the AFL in its fundamental priority of looking after the health and welfare of players. He shares his concern over the serious circumstances which gave rise to the supplements saga at the Essendon Football Club ... The AFL accepts Dr Reid’s position and withdraws all charges against him, without penalty." Hird remained on the Essendon payroll and received his full salary during the suspension. The AFL initially demanded that the payments stopped when they were made public in December 2013 but acquiesced after determining that its legal position was weak. In Hird's absence, Mark Thompson stepped up to serve as senior coach in the 2014 season. At the time of the penalties for governance failures, no charges were laid against any players, whether or not banned substances had been used was unproven, and the ASADA and AFL investigation remained open.
Sources: en.wikipedia.org
=== Slowing circadian oscillations === Deuterium has been shown to lengthen the period of oscillation of the circadian clock when dosed in rats, hamsters, and Gonyaulax dinoflagellates. In rats, chronic intake of 25% 2H2O disrupts circadian rhythm by lengthening the circadian period of suprachiasmatic nucleus-dependent rhythms in the brain's hypothalamus. Experiments in hamsters also support the theory that deuterium acts directly on the suprachiasmatic nucleus to lengthen the free-running circadian period.
== History == Transaid was founded in 1998 by Save the Children, the Chartered Institute of Logistics and Transport (CILT), and its patron, Anne, Princess Royal. It is a UK‑based international development charity focused on transforming lives through safe, available, and sustainable transport in sub‑Saharan Africa. The charity operates multiple programmes in several countries, working with governments, communities, and industry partners to improve road safety, transport management, and access to healthcare. In recent years, Transaid has been active in motorcycle helmet safety in Kenya through its Kenya National Helmet Wearing Coalition, working with the FIA Foundation and others to build enforcement of helmet standards, establish awareness among riders, and to set up a helmet testing laboratory in East Africa. The charity has also launched its Christmas Appeal 2025 to raise funds from individuals and businesses for road safety and healthcare access across sub‑Saharan Africa; in that appeal, it reported having trained over 9,000 professional drivers and riders, delivered thousands of eye tests, and supported minibus‑taxis adopting safety charters. Additionally in early 2025, Princess Anne opened the new London office of Arbuthnot Latham, a corporate partner of Transaid, emphasising the strengthening of corporate backing and visibility for the charity.
Over a two-year period, close to $800 million worth of fentanyl was illegally sold online to the US by Chinese distributors. The drug is usually manufactured in China, then shipped to Mexico, where it is processed and packaged, which is then smuggled into the US by drug cartels. A large amount is also purchased online and shipped through the US Postal Service. It can also be purchased directly from China, which has become a major manufacturer of various synthetic drugs illegal in the US. AP reporters found multiple sellers in China willing to ship carfentanyl, an elephant tranquilizer that is so potent it has been considered a chemical weapon. The sellers also offered advice on how to evade screening by US authorities. According to Assistant US Attorney Matt Cronin in 2019:
Sources: en.wikipedia.org
In the United States, opium poppies and poppy straw are prohibited. As the opium poppy is legal for culinary or aesthetic reasons, poppies were once grown as a cash crop by farmers in California. The law of poppy cultivation in the United States is somewhat ambiguous. The reason for the ambiguity is that the Opium Poppy Control Act of 1942 (now repealed) stated that any opium poppies should be declared illegal, except if the farmers were issued a state permit. § 3 of the Opium Poppy Control Act stated: It shall be unlawful for any person who is not the holder of a license authorizing him to produce the opium poppy, duly issued to him by the Secretary of the Treasury in accordance with the provisions of this Act, to produce the opium poppy, or to permit the production of the opium poppy in or upon any place owned, occupied, used, or controlled by him. This led to the Poppy Rebellion, and to the Narcotics Bureau arresting anyone planting opium poppies and forcing the destruction of poppy fields of anyone who defied the prohibition of poppy cultivation. Though the press of those days favoured the Federal Bureau of Narcotics, the state of California supported the farmers who grew opium poppies for their seeds for uses in foods such as poppy seed muffins. Today, this area of law has remained vague and remains somewhat controversial in the United States. The Opium Poppy Control Act of 1942 was repealed on 27 October 1970. Under the Federal Controlled Substances Act, opium poppy and poppy straw are listed as Schedule II drugs under ACSN 9630.
After the Qatari Ministry of Defence announced on 2 March that two Iranian drones attacked Qatari gas facilities, followed closely by an announcement from QatarEnergy that all gas production in the country had been halted, European natural gas prices nearly doubled. This raised concerns over energy security and fertiliser costs. EU natural gas prices decreased again to a less-high €48/MWh on Wednesday 4 March. The Iran conflict also bolstered the necessity for renewable energy, as solar and wind power can reduce vulnerability to external supply and decentralised power generation that offers greater autonomy from global energy markets. With fluctuating oil prices, renewable energy has become significantly more cost-competitive. April 2026 was the strongest month of electric vehicle sales on record in Europe. Shell plc's CEO warned that Europe could face shortages of fuel by April. British supermarket chain Asda warned that it was already facing shortages of fuel at their fuel stations. In addition to broader fuel supply disruptions, reports in April 2026 indicated significant impacts on global energy and aviation markets linked to tensions in the Strait of Hormuz during the Iran–United States conflict. Restricted maritime traffic was reported to have contributed to supply constraints in oil and jet fuel, affecting global energy flows and increasing market volatility. The disruption contributed to sharp increases in global energy prices.
== Causes == Childhood obesity can be brought on by a range of factors which often act in combination. "Obesogenic environment" refers to a mixture of environmental factors that are permissive of obesity, especially for those who are genetically predisposed. The greatest risk factor for child obesity is the obesity of both parents. This may be reflected by the family's environment and genetics. Other reasons may also be due to psychological factors and the child's body type. A 2010 review stated that childhood obesity likely is the result of the interaction of natural selection favouring those with more parsimonious energy metabolism and today's consumerist society with easy access to cheap, energy-dense foods and less energy requirements in daily life. Factors include the increase in use of technology, increase in snacks and portion size of meals, and the decrease in the physical activity of children. A study found that children who use electronic devices three or more hours a day had between a 17–44% increased risk of being overweight, or a 10–61% increased risk of obesity (Cespedes 2011). Childhood obesity is common among children from low-income, African American and Hispanic communities. This is mainly because minority children spend less time playing outside the house and staying active. Parents may prefer their children stay inside the home because they fear gang and drug violence and other dangers.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.